Search

Treatment perspectives for non-small cell lung cancer (NSCLC) have been significantly expanded by the integration of immune checkpoint inhibitors into multimodal therapy concepts. Currently, combined, immune checkpoint-inhibitor-based therapy concepts are also advancing into early, resectable stages of NSCLC. Neoadjuvant and perioperative chemoimmunotherapy opened up a promising new preoperative treatment approach, but also raises some new questions and challenges. With the expanded perioperative treatment options and the perspective on a further improvement in the absence of recurrence after tumor resection, there is push towards comprehensively collecting therapy-relevant findings for imaging, molecular and histopathological diagnostics at an early stage. All patients with lung carcinoma, regardless of the therapy intention, should be presented to an interdisciplinary tumor board with thoracic oncological expertise. This is regularly given in certified lung cancer centers.A standardized procedure contributes to optimized pre-therapeutic diagnostics and facilitates coordination for the best possible multimodal approach in the interdisciplinary tumor board. In the case of centrally located resectable tumors, for example, neoadjuvant treatment increases the chances of a procedure that is as parenchymal sparing as possible. Some questions cannot yet be answered conclusively. Perioperative systemic therapy with molecular-targeted and immune checkpoint inhibitors is the subject of numerous ongoing studies. The considerable dynamics in newly approved therapies and the development of perioperative therapy concepts require continuous adaptation of diagnostic algorithms and standards. Integration into standard pre-surgical routine makes rapid classification of the relevant findings as well as close coordination between the diagnostic and interventional disciplines essential., Competing Interests: KW: Aktienbesitz (AstraZeneca, Roche, Pfizer, BMS, Bayer, Novartis, J&J); indirekte Interessen (Präsidentschaft DGT 2021-23; VS-Mitgliedschaft DGT, DGCH; VS Mitgliedschaft ESTS); Mitarbeit an Advisory Boards/Data Safety Monitoring Boards (AstraZeneca, BMS, Roche, J&J). DJ: Erstattung von Fortbildungsbeiträgen. AD: Honorare für Vortragstätigkeit (Takeda); Mitarbeit an Advisory Boards/Data Safety Monitoring Boards (BMS). CKS: Honorare für Beratungstätigkeit (AstraZeneca, Amgen, BMS, Daiichi-Sankyo, MSD, onkowissen, Roche, Sanofi), Honorare für Vortragstätigkeit (Amgen, AstraZeneca, Art tempi/medtoday, BMS, Daiichi-Sankyo, MSD, Lilly, Novartis, onkowissen, Pfizer, Roche, Sanofi, Streamed Up, Takeda); indirekte Interessen (AIO, POA, SDGP); Reise-/Tagungskostenzuschüsse (Amgen, AstraZeneca, BMS Boheringer Ingelheim, Janssen). AS: Honorare für Vortragstätigkeit; Mitarbeit an Advisory Boards (Aignostics, Amgen, Astellas, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, QuiP, Roche, Sanofi, Seagen, Servier, Takeda, Thermo Fisher); Förderung von Forschungsvorhaben (Bayer, BMS, Chugai, Incyte). AT: Honorare für Beratungstätigkeit; Honorare für Vortragstätigkeit (AstraZeneca, Boehringer Ingelheim, BMS, Daiichi-Sankyo, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi); indirekte Interessen (AIO, ERS); Reise-/Tagungskostenzuschüsse (AstraZeneca, BMS, Daiichi-Sankyo, MSD, Janssen, Sanofi). MZ: Honorare für Beratungstätigkeit (AstraZeneca, BMS, Novocure); Honorare für Vortragstätigkeit (AstraZeneca); Mitarbeit an Advisory Boards (AstraZeneca, BMS); Reise-/Tagungskostenzuschüsse (AstraZeneca, BMS). MT: Förderung von Forschungsvorhaben (AstraZeneca, BMS, Merck, Roche Takeda); Honorare für Beratungstätigkeit; Mitarbeit an Advisory Boards (Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Daiichi-Sankyo, GSK, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda); Honorare für Vortragstätigkeit; Mitarbeit an Advisory Boards (Amgen, AstraZeneca, Beigene, BMS, Boehringer Ingelheim, Celgene, Chugai, Daiichi-Sankyo, GSK, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda); Reise-/Tagungskostenzuschüsse (AstraZeneca, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda)., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)

The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on the early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present key points for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process. CITATION FORMAT: · Vogel-Claussen J, Blum TG, Andreas S et al. Position paper on the implementation of a nationally organized program in Germany for the early detection of lung cancer in high-risk populations using low-dose CT screening including the management of screening findings requiring further workup. Fortschr Röntgenstr 2024; 196: DOI 10.1055/a-2178-2846., Competing Interests: T. G. B. gibt eine Forschungsförderung von EU4Health an.J. V.-C. gibt Forschungsförderungen von BMBF, NIH, AstraZeneca, Siemens Healthineers, GlaxoSmithKline und Boehringer Ingelheim sowie Vortrags- oder Beratungshonorare von AstraZeneca, Siemens Healthineers, GlaxoSmithKline und Boehringer Ingelheim an.S. A. gibt eine Mitarbeit im Aktionsbündnis Nichtraucherschutz und in der Task Force Tabakentwöhnung der DGP an.H.-U. K. gibt Forschungsförderungen von Siemens, Philips und Boehringer Ingelheim sowie Vortrags- oder Beratungshonorare von Siemens, Boehringer Ingelheim, Philips, Sanofi und Median an.Alle weiteren Autorinnen und Autoren haben keine potenziellen COI angegeben., (Thieme. All rights reserved.)

The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present concrete cornerstones for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process., Competing Interests: T. G. B. gibt eine Forschungsförderung von EU4Health an.J. V.-C. gibt Forschungsförderungen von BMBF, NIH, AstraZeneca, Siemens Healthineers, Glaxo Smith Kline und Boehringer Ingelheim sowie Vortrags- oder Beratungshonorare von AstraZeneca, Siemens Healthineers, GlaxoSmithKline und Boehringer Ingelheim an. S. A. gibt eine Mitarbeit im Aktionsbündnis Nichtraucherschutz und in der Task Force Tabakentwöhnung der DGP an.H.-U. K. gibt Forschungsförderungen von Siemens, Philips und Boehringer Ingelheim sowie Vortrags- oder Beratungshonorare von Siemens, Boehringer Ingelheim, Philips, Sanofi und Median an.Alle weiteren Autorinnen und Autoren haben keine potenziellen COI angegeben., (Thieme. All rights reserved.)

The process of implementing early detection of lung cancer with low-dose CT (LDCT) in Germany has gained significant momentum in recent years. It is expected that the ordinance of the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection (BMUV) on early detection of lung cancer, which has been commented on by the professional societies, will come into effect by the end of 2023. Based on this regulation, the Federal Joint Committee (G-BA) will set up a program for early lung cancer detection with LDCT in the near future. In this position paper, the specialist societies involved in lung cancer screening present concrete cornerstones for a uniform, structured and quality-assured early detection program for lung cancer in Germany to make a constructive contribution to this process., Competing Interests: T.G.B. gibt eine Forschungsförderung von EU4Health an.J.V.-C. gibt Forschungsförderungen von BMBF, NIH, AstraZeneca, Siemens Healthineers, GlaxoSmithKline und Boehringer Ingelheim sowie Vortrags- oder Beratungshonorare von AstraZeneca, Siemens Healthineers, GlaxoSmithKline und Boehringer Ingelheim an. S.A. gibt eine Mitarbeit im Aktionsbündnis Nichtraucherschutz und in der Task Force Tabakentwöhnung der DGP an.H.-U.K. gibt Forschungsförderungen von Siemens, Philips und Boehringer Ingelheim sowie Vortrags- oder Beratungshonorare von Siemens, Boehringer Ingelheim, Philips, Sanofi und Median an.Alle weiteren Autorinnen und Autoren haben keine potenziellen Interessenkonflikte angegeben., (Thieme. All rights reserved.)

Localized solitary fibrous tumors are a rare entity and are mostly found in the thorax, but can also occur in the liver, skin, meninges, peritoneum, and pericardium. Making the diagnosis is often difficult because of the various micromorphologic outlooks. The histopathological assessment with differentiated immunohistochemistry is decisive. Surgical resection of the localized solitary fibrous tumors is the therapy of choice. The recurrence and metastasis rates depend on the histological dignity and are in total very low. Therefore, continuous follow-up examinations are indicated. We report on a 76-year-old female patient with a monstrous solitary fibrous tumor of the pleura who complained of exertional dyspnea and sharp pain in the right thoracic region for several weeks. Computed tomography showed a massive, heterogeneous pulmonary mass 22 cm in diameter in the middle and lower field of the right lung with compression of the diaphragm and mediastinum. The tumor was completely resected through a double thoracotomy in the 5th and 8th ICR. Intraoperatively, the tumor was stalked to the middle lobe. In order to completely remove the tumor, a wedge resection was also performed from the middle lobe. The tumor weighed 2.4 kg. The diagnosis of a solitary fibrous tumor of the pleura was made histologically and immunohistochemically. Postoperatively, the lung has fully expanded. There was no evidence of a relapse at the 3-month follow-up examination. The clinical symptoms, diagnosis, treatment options, risk of recurrence and the prognosis of these tumors are shown and discussed in accordance with the literature., Competing Interests: Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht., (Thieme. All rights reserved.)

Background: Earlier studies have proven that in patients with non-small cell lung cancer video-assisted thoracoscopic surgery is functionally superior to thoracotomy in terms of perioperative and postoperative complications. The objective of this work was to determine whether there is a difference in health-related quality of life (HRQoL) of patients with non-small cell lung cancer - compared to the German normal population - before and after surgery. Moreover, HRQoL after thoracotomy was compared to HRQoL after video-assisted thoracoscopic surgery (VATS)., Material and Methods: Based on retrospective data generated during a 7-year period (2010 - 2017), 327 patients with non-small cell lung cancer who underwent therapy were examined. Patients either underwent thoracotomy or video-assisted thoracoscopic surgery. 456 of short form 12 questionnaires were analysed. Via norm-based scoring, and physical and mental component summaries (PCS and MCS) were calculated before and 6, 12, and 24 months after treatment. Using t tests, potential differences in physical and mental component summaries were evaluated between patients and the German normal population as well as between patients after thoractomy and after VATS., Results: Up to 24 months after surgery, the physical dimension of HRQoL is significantly reduced, while the mental component summary does not significantly differ from the German population. Moreover, thoracotomy and VATS gave equivalent values for health-related quality of life., Conclusion: With respect to health-related quality of life, thoracotomy and video-assisted thorascopic surgery are equivalent in the long term. But there was a trend to improvement with both summary scores that might indicate superiority of video-assisted thoracoscopic surgery., Competing Interests: Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht., (Thieme. All rights reserved.)

The treatment of pain after thoracic surgery is a challenge and takes place in the individual clinics mostly according to clinic internal standards. It exists no currently valid S3 guideline for the treatment of acute perioperative and posttraumatic pain. For an effective pain treatment as well individual pain experience as the pain intensity of the various thoracic surgical procedures must be considered. Regular pain assessment with appropriate methods and their documentation form the basis for adequate and adapted pain therapy.There are a number of different pain therapy methods, non-medicamentous and drug-based methods, whose effectiveness is described in the literature partially different. For the treatment of acute postoperative pain after thoracic surgery, mainly drug-related procedures are used, except for physiotherapy as a non-medicamentous method. Increasingly, alternative procedures for the peridural catheter as a therapeutic gold standard in the treatment of pain after thoracic surgery are used. Their application can be integrated into a therapeutic algorithm., Competing Interests: Interessenkonflikt: Die Kosten für die statistische Auswertung der im Text erwähnten Schmerzstudie der Autoren wurden von der Firma Pajunk übernommen., (Georg Thieme Verlag KG Stuttgart · New York.)

More and more women suffer from lung cancer. In comparison to the male patients they are younger and more likely never-smokers. Adenocarcinomas are more frequently in women than in men. Their long-time survival post curative resection in early stage non-small-cell lung cancer is better than in men. Women show frequently more molecular changes: more molecular targets are found. Therefore they might benefit more from target-oriented stratified medical treatments. This overview comments on the gender-specific differences in diagnostics, treatment and outcome of lung cancer., (Georg Thieme Verlag KG Stuttgart · New York.)

Systemic air embolism is known to rarely complicate blunt chest trauma. However, cerebral infarction caused by air emboli possibly originating from a traumatic pneumatocele has not been previously reported. We report a case of a 46-year-old woman who sustained blunt chest trauma with multiple rib and clavicular fractures, hemothorax and a huge, tense traumatic pneumatocele. She subsequently developed clinical and radiologic features of cerebral infarction. The cerebral infarct is likely to be secondary to cerebral air embolism originating from a traumatic pneumatocele., (Georg Thieme Verlag KG Stuttgart · New York.)

Aspiration of foreign bodies is extremely rare in adults, but it may occur during the course of dental treatment and become a serious problem for the patient. A case of a 77-year old man with chronic cough after dental treatment and unrecognised aspiration of an implant is presented. The implant remained unidentified for three years as an endobronchial foreign body of the lower lobe bronchus. A bronchoscopic removal failed and surgery was indicated for lobectomy of the right lower lobe because of chronic pneumonia. A review of prevention, signs and symptoms, management and documentation of the complications is presented.

Background: A critical look at the effectiveness of medical procedures and therapies is important with the increasing limitations on resources in health care., Method: The costs for treatment and the quality of life according to the SF-36 were analyzed in a retrospective health economic study on 65 patients who had undergone surgery for primary non-small-cell lung cancer., Results: The mean cost for all patients was 7,169 euro per patient. 38.8 % resulted from surgery, 31.6 % were attached to the preoperative phase on the general ward, 11 % postoperatively to the general ward. Intensive care costs accounted for 18.7 %. The cost of each surgical procedure ranged from 4,634 euro for a pneumonectomy to 8,366 euro for a lobectomy with sleeve resection of the bronchus. The most expensive factors were staff, disposable materials, pathological investigations, and radiology services. There was no difference in these proportions with stage of tumor or the surgical procedures undertaken. Quality of life as assessed by the SF-36 questionnaire ranged from 31.82 (physical functioning) to 75.0 (social functioning) one year after the operation. These scores were lower than for those with other chronic diseases. On average, 4.62 quality-adjusted life years were achieved. The cost per QALY was 1,970 euro. The extent of resection and the tumor staging correlates significantly with the mean cost per QALY., Conclusion: Thoracic surgery is cost intensive. With increasing staging of the tumor, the cost for treatment increased as with increased operation complexity.

Tumors of the diaphragm are rare and caused by there special localisation difficult to diagnose. We describe the case of a 31 year old man with a choristoma of the left diaphragmal crux where the localisation and genesis could only be cleared through lateral thoracotomy. Nor the CT guided puncture or the laparoscopy-although sufficient samples for the pathology could be gained-allowed the right diagnose. The importance of good diagnostic approach to select the right operative procedure-in this case the anterolateral thoracotomy-is described.